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Abstract The aim of the studywas to test the frequency of
CD4? CD25
highFoxP3 regulatory T cells in JIA patients
and to assess their activation status and functional activity.
The study involved 12 children with JIA and 35 healthy
control subjects. PBMC were stained with monoclonal
antibodies (anti-CD25, anti-CD4, anti-CD127, anti-CD69,
anti-CD71, and anti-FoxP3). The samples were evaluated
using ﬂow cytometer. CD4? CD25- and CD4?
CD25? cells were isolated by negative and positive
selection with magnetic microbeads. CD4? CD25? and
CD4? CD25- cells were cultured separately and co-cul-
tured (1:1) with or without PHA. The percentage of Tregs in
JIA patients was signiﬁcantly decreased in comparison with
controls (median, 3.2 vs. 4.6; P = 0.042). Relative ﬂuo-
rescence intensities of FoxP3 were higher in JIA patients
than in controls (median, 9.1 vs. 6.8). The percentage of
activated Tregs (CD71?) was signiﬁcantly higher in JIA
patients in comparison with controls (median, 6.5 vs. 2.8;
P = 0.00043). CD4? CD25? cells derived from JIA
patients and controls were anergic upon PHA stimulation,
while CD4? CD25- cells showed intensive proliferative
response. The proliferation rate of CD4? CD25- cells
stimulated by PHA was decreased in co-cultures. In JIA
patients, the inhibition of proliferation of CD4? CD25-
cells by CD4? CD25? cells was 37.9%, whereas in
controls it was signiﬁcantly lower (55.7%, P = 0.046). JIA
patients had statistically lower percentage of Tregs in
peripheral blood compared to controls. CD4? CD25? cells
sorted from peripheral blood of JIA patients had statistically
lower ability to suppress CD4? CD25- cell proliferation
in comparison with cells obtained from controls.
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Introduction
Juvenile idiopathic arthritis (JIA) belongs to the group of
connective tissue diseases. This is the most common
chronic autoimmune disease in children [1–4]. The etiol-
ogy of this type of chronic arthritis in children is unknown.
The incidence of JIA is assessed for approximately
2.6–13.9/100,000 children/year among Caucasian children
below 15 years of age, with a prevalence of approximately
6.5–113/100,000 children [4].
In the Classiﬁcation Criteria of the International League
of Associations for Rheumatology (ILAR), JIA is regarded
not as a single disease but as a category of diseases with
three principal types of onset: (1) oligoarthritis or pauc-
iarticular disease (OA), (2) polyarthritis (PA), and (3)
systemic-onset disease (SO) [4]. Six distinct subtypes are
identiﬁed. ILAR propose an additional deﬁnition and
classiﬁcation schema (age at onset \16 years; arthritis in
C1 joints; duration of disease is C6 weeks; onset type
deﬁned by type of articular involvement in the ﬁrst
6 months after onset: polyarthritis, oligoarthritis, systemic
disease, psoriatic arthritis, enthesitis-related arthritis and
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arthritis) [3, 5, 6]. Full pathogenesis of JIA is still a matter
of investigation. Some already known reasons are genetic
and environmental factors, infections, and also deregula-
tion of immune system, which results in autoreactivity
[3, 5].
To maintain peripheral tolerance, the immune system
has evolved a number of regulatory mechanisms. Failure of
this regulatory network can result in autoimmune disease
development. The most important cells in the immune
system regulation are CD4? CD25
high regulatory T
(Tregs) cells. They can control autoagressive T cells and B
cells, which somehow escape from negative selection in
thymus. They can block activation and effector functions of
autoreactive T cells [7–12].
In human, Tregs were identiﬁed in both peripheral blood
and thymus. Only these CD4? CD25? T cells that express
high levels of CD25 display regulatory functions [13, 14].
Tregs are divided into several populations. Naturally
occurring Tregs, which express the forkhead transcription
factor (FoxP3), are found in thymus and in peripheral
blood, where they account for 5–10% of CD4? T cells.
FoxP3 is a crucial factor responsible for the development
of Tregs in the thymus. It is also needed to maintain the
suppressive activity of mature peripheral Tregs and is a
speciﬁc molecular marker for Tregs in human peripheral
blood. Decreased FoxP3 expression causes conversion of
Tregs into effector cells. The last phenomenon can be
responsible for autoimmune diseases development [15].
FoxP3 expression in Tregs plays a crucial role in main-
taining immunological tolerance [16, 17].
There are suggestions that in rheumatoid arthritis (RA)
and JIA, Tregs function is impaired. However, the studies
concerning regulatory T cells in RA or JIA are rather
ambiguous. In some papers the authors report decreased
number of regulatory T cells in peripheral blood in patients
with RA or JIA [12, 18, 19], whereas others show just the
opposite—increased number of these cells [20]o rn o
changes in Tregs number [21, 22]. Moreover, there are so
many variances in data concerning Tregs in JIA and RA
patients because of no speciﬁc criteria to identify these
cells. Some authors analyzed whole population of
CD4CD25 cells, but not exactly CD4CD25
high. Some did
not use FoxP3 expression as a speciﬁc marker for regula-
tory T cells [21–24].
As it is suggested by many authors, FoxP3 expression is
crucial for the identiﬁcation of cells bearing suppressive
activity [25–27]. However, FoxP3 alone is not sufﬁcient to
mark off this speciﬁc subpopulation. The remaining Tregs’
antigens (for example, CD152 and GITR) are not expressed
in the whole population. Solely, CD4 and high expression of
CD25 are characteristic of all Tregs. However, the assess-
ment and exact gating of cells with high expression of CD25
is very subjective and depend on the person who performs
ﬂow cytometry analysis or who analyze the results. In many
situations, there is no distinct borderline between CD25
low
and CD25
high populations. Some authors use additional
factors such as CD3 and CD4 expression, which is a little
lower on CD25
high T cells [18]. Importantly, the population
of CD4CD25
high cells includes FoxP3 negative cells that are
recognized as activated T cells. In this situation, the
assessment of CD127 expression can be very useful
[28–30]. According to Seddiki et al. [30] and Liu et al. [29],
CD127 is downregulated in Tregs. A strong, statistically
signiﬁcant correlation between FoxP3 and CD127
low was
found in CD4CD25 T cells in humans. It provides a pos-
sibility to separate activated T cells, which are CD127
positive, from Tregs, which are CD127
low or negative.
Hence, CD127 can be useful marker used in the puriﬁcation
of CD4? CD25
highFoxP3 ? T cells population.
According to Ruprecht et al. [31], CD27 can also be a
good marker of Treg cells useful to distinguish them from
conventional CD4? cells. CD27 antigen is lost by these
cells upon terminal differentiation [32] and as was proven
by Ruprecht et al. [31], the combination of CD25 and
CD27 antigens allows identifying most of Tregs
(CD4? CD25
highCD27?).
Important activity of Tregs is their ability to suppress
effector T cells and to limit their inﬂammatory function. It
was documented that Tregs obtained from patients with RA
are defective in their ability to suppress cytokine produc-
tion (TNF-a, INF-c)[ 21]; however, the results concerning
this issue are controversial. Nevertheless, there is general
agreement concerning one question: synovial ﬂuid (SF)
of JIA patients contains high number of Tregs [12, 23, 31,
33].
Activation status of Tregs is unclear. Some authors
report lack of activation markers expression (e.g., CD69 or
CD71) on Tregs’ surface [34], but the others documented
their expression on Tregs [13] or even increased CD69
expression after speciﬁc therapy [35]. Cao et al. [33]
described the presence of CD71 antigen on PMBC and SF
Tregs in patients with RA.
Taking all these facts into consideration, the aim of this
study was not only to test the frequency but also to assess
the activation status and functional activity of
CD4? CD25
highFoxP3 regulatory T cells in JIA patients.
The study was approved by Independent Ethics Com-
mittee of the Medical University of Warsaw.
To perform proliferation assays, we needed to collect at
least 8 ml of peripheral blood to assure the separation of
sufﬁcient number of cells used for co-cultures. Due to
ethical reasons, we included only 14-year-old or older
children (n = 7) in the study. Blood collected from healthy
adults served as a control, because the immunological
systems of such children and adults are very similar.
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Patients
The study involved 12 children with JIA (treated in the
Department of Pediatrics, Medical Centre of Postgraduate
Education, Warsaw, and Clinic and Polyclinic of Rheu-
matology of Developmental Age, Institute of Rheumatol-
ogy, Warsaw), 29 healthy children, and 6 healthy adult
volunteers. Table 1 shows the clinical characteristics of
children with JIA and healthy controls.
The patients with JIA were in active phase of disease
and fulﬁlled the classiﬁcation criteria of the ILAR from
Durban 1997 published by Petty et al. [3]. None of the
patients was treated with glicocorticosteroids, because
prednisolone or other drugs from this group may affect
lymphocyte functions and CD25 expression [36].
Methods
From young children with JIA and healthy control chil-
dren, 0.5–2.0 ml of heparinized blood was collected from
antecubital vein. From children over 14 years old and
from adult volunteers, 8 ml of heparinized blood was
collected.
Cells
Peripheral blood mononuclear cells (PBMC) were isolated
using a standard Ficoll-Histopaque
-1077 (Sigma–Aldrich
Co., St. Louis, USA) gradient centrifugation (Sigma
Diagnostic Instruction Manual). Cells’ concentration was
adjusted to 1 9 10
6/ml in control culture medium
(RPMI1640 supplemented with 10% FCS, 200 mM L-glu-
tamine, and 1 ml of 1 M HEPES). The procedures were
performed in sterile conditions. Viability of blood lym-
phocytes was determined by trypan blue staining and
achieved approximately 95–98%.
Proceedings of FoxP3 expression
in CD4? CD25
highCD127- T cells examination,
and the assessment of CD4? CD25
high T cells
activation
Freshly isolated 100 llo f19 10
6/ml PBMC was stained
with 5 or 10 ll of monoclonal antibodies (according to
manufacturer’s instructions, BD-Pharmingen) in 2 tubes:
tube no. 1—anti-CD25 PE-Cy7, clone M-A251; anti-
CD4 PE-Cy-5; and anti-CD127 PE
tube no.2—anti-CD69 PE; anti-CD71 FITC; anti-CD25
PE-Cy7, clone M-A251; and anti-CD4 PE-Cy-5.
Both tubes were incubated for 20 min in the dark at
room temperature. Cells were washed twice in washing
buffer (PBS supplemented with 0.5% inactivated FBS) for
5 min, 250 g.
FoxP3 intracellular staining was performed in tube 1
according to manufacturer’s instruction (BD-Pharmingen).
Brieﬂy, cells were incubated for 10 min in the dark at room
temperature with 2 ml of buffer A, then washed in washing
buffer for 5 min, 500 g, and incubated for 30 min in 500 ll
of buffer C in the dark at room temperature. Subsequently,
the cells were stained with 20 ll anti-FoxP3 monoclonal
antibody (Alexa Flour 488, BD-Pharmingen) for 30 min in
the dark at room temperature and washed twice.
Flow cytometric analysis
The appropriate isotype controls were included. The sam-
ples were evaluated within 24 h on Cytomics FC500 ﬂow
cytometer (Beckmann Coulter).
Table 1 Clinical characteristics
of children with JIA and healthy
controls
Children
with JIA
Healthy
controls
children
Healthy
controls
adults
Number 12 29 6
Men 3 7 2
Women 9 14 4
Age (mean, SD, years) 9.6 ± 5.57 8.3 ± 4.88 41.0 ± 15.15
Type of onset
Polyarthritis 7
Oligoarthritis 5
Disease duration (mean, SD, months) 11.0 ± 12.82
CRP (above reference value) 5/12
ESR (above reference value) 9/12
RF positive (any time) 0/12
Antinuclear antibodies 2/12
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CD4? cells were isolated from freshly isolated PBMC by
negative selection according to manufacturer’s protocol
(MACS, MiltenyiBiotech). Brieﬂy, PBMC were incubated
for 20 min in 4C with biotin monoclonal antibodies
cocktail (10 ll/10
7 cells) against: CD8, CD14, CD16,
CD19, CD36, CD56, CD123, TCRc/d, and CD235a
(MiltenyiBiotech). Then, the cells were incubated for
15 min in 4C with antibiotin-labeled microbeads (20 ll/
10
7 cells) and washed twice in washing buffer (10 min,
300 g) and depleted using MACS LD column.
The obtained CD4? T cells were washed twice in
washing buffer (10 min, 300 g) resuspended and labeled
with 10 ll of anti-CD25 microbeads (10 ll/10
7 cells).
Subsequently, the cells were incubated for 15 min in 4C.
After the incubation, 10 ll of anti-CD25 PE monoclonal
antibody and 5 ll of anti-CD4FITC (BD-Pharmingen)
monoclonal antibodies were added. The cells were then
incubated for the next 15 min at 4C and washed twice in
washing buffer. Then CD4? T cells were positively
selected using MACS MS column according to manufac-
turer’s protocol (MACS, MiltenyiBiotech).
After the last centrifugation, the selected subpopulations
of CD4? CD25- and CD4? CD25? T cells were resus-
pended in culture medium (RPMI 1640 supplemented with
10% FCS, L-Glutamine 200 mM, HEPES 1 M, antibiotic–
antimycotic) and were immediately used in proliferation
assay.
Proliferation assay
We cultured 1 9 10
5 of the selected CD4? CD25- or
CD4? CD25? T cells, resuspended in 100 ll of culture
medium, in sterile plastic 96-well, ﬂat-bottom microwell
culture plates–Nunclon (Nunc A/S, Denmark) at 37C
at 95% humidity and in an atmosphere containing 5%
CO2.
For proliferation analysis, CD4? CD25? and CD4?
CD25- T cells were cultured separately, 100 ll of control
medium with or without phytohaemagglutinin (PHA)
(Sigma–Aldrich) was added to the appropriate wells. The
ﬁnal concentration of PHA was 20 lg/ml.
For suppression analysis CD4? CD25- and CD4?
CD25? T cells were co-cultured at 1:1 ratio (0.5 9 10
5 ?
0.5 9 10
5) in the same conditions.
After 54 h of culture, 1 lCi/well
3H-thymidine was
added for the remaining 18 h of culture. Cells were har-
vested using cell harvester (Skatron, Norway). Proliferation
was measured using a liquid scintillation counter LKB
Wallac 1409 (RackBeta LKB, Sweden).
For proliferation inhibition analysis, the CD4? T cells
puriﬁed from peripheral blood were separated into CD25-
and CD25? populations and subsequently cultured with or
without PHA.
Proliferation index was counted as follows:(cmp of
3[H] Thymidine incorporation of cells cultured with PHA–
cmp of
3[H] Thymidine incorporation of cells cultured
without PHA)/cmp of
3[H] Thymidine incorporation of
cells cultured without PHA
Proliferation index of 1 9 10
5 cells was divided into 2
to get a proliferation index of 0.5x10
5.
Percentage of inhibition of proliferative response was
counted as follows:
Statistical analysis
All of the measured parameters had nonparametric distri-
bution (according to Shapiro–Wilk’s criteria), so statistical
analysis was performed using nonparametric Wilcoxon test
for dependent samples and nonparametric Mann–Whitney
U test for independent samples. To assess the correlations
between results, Spearman’s test was used.
Results
Percentages of CD4? CD25
highFoxP3 ? regulatory T
cells in peripheral blood of JIA patients and healthy
controls
Tregs in peripheral blood were identiﬁed as CD4?
CD25?
highFoxP3 ? CD127- T cells. The number of
regulatory T cells is expressed as a percentage of all CD4?
T cells.
As shown in Fig. 1, the percentage of Tregs in JIA
patients was signiﬁcantly decreased in comparison with
healthy controls (median (25 percentile; 75 percentile): 3.2
(2.09; 4.78) vs. 4.6 (3.61; 5.81), respectively, P = 0.042).
All JIA patients suffered from one of two subtypes of
JIA: OA (n = 5) and PA (n = 7). No differences between
the percentages of Tregs in peripheral blood of the
100%  
CD4 þ CD25 cellsco culturedwithCD4 þ CD25 þ cellsproliferationindex   100
CD4 þ CD25 cellsproliferationindex
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(25 percentile; 75 percentile): OA 4.4 (1.89; 5.55), PA 2.7
(2.29; 3.58)).
Relative ﬂuorescence intensities (RFI) of FoxP3
expression were also compared. RFI was calculated using
the following formula: experimental mean ﬂuorescence
intensity (MFI)/MFI with isotype control antibody
according to Dechant et al. [37]. We saw higher RFI of
FoxP3 expression in JIA patients than in healthy controls
(median (25 percentile; 75 percentile): 9.1 (7.24; 11.22),
6.8 (5.59; 9.51), respectively). The results are shown in
Fig. 2.
The comparison of total population of CD4? CD25? T
cells in JIA patients and healthy controls did not reveal any
differences (about 14% of CD4 T cells were CD25 posi-
tive). Additionally, the percentage of lymphocytes (median
(25 percentile; 75 percentile): 36.0 (28.50; 46.00), 42.7
(31.40; 52.50) and the percentage of CD4FoxP3 cells
(median (25 percentile; 75 percentile): 6.4 (2.87; 8.48), 6.8
(5.70; 9.19)) were not different.
Activation status of CD4? CD25
high T cells–
expression of CD69 and CD71 on CD4? CD25
high
T cells
In the performed experiments, we assessed CD71 and
CD69 expression on CD4? CD25
high T cells without
analyzing FoxP3 or CD127 expression. Fig. 3 shows the
percentages of activated Tregs, which express CD71 anti-
gen on the surfaces. We found signiﬁcantly higher
expression of this antigen on Tregs from JIA patients than
in healthy controls (median (25 percentile; 75 percentile):
6.5 (3.83; 13.13) vs. 2.8(1.47; 4.31), respectively,
P = 0.00043).
When we compare CD69 expression on Tregs, the
percentages of activated Tregs were similar in JIA patients
and in healthy controls (median (25 percentile; 75 per-
centile): (3.5 (1.30; 6.04) vs. 3.1(1.90; 4.34), respectively).
Inhibition of proliferation of CD4? CD25- T cells
by CD4? CD25? T cells
CD4? CD25? T cells derived from peripheral blood of
JIA patients and healthy controls were anergic upon PHA
stimulation (proliferation index: -0.36 (-0.39; 0.05), 0.04
(-0.41; 0.35), respectively), CD4? CD25- T cells
showed very intensive proliferative response (proliferation
index: 78.7 (47.68; 382.79), 87.0 (62.68; 168.23),
respectively).
Proliferation of CD4? CD25- T cells stimulated by
PHA was decreased in cultures when CD4? CD25? T
cells were added in 1:1 ratio (proliferation index: 55.2
 Median 
 25%-75% 
 Min - Max  JIA Control group
0
1
2
3
4
5
6
7
8
%
 
o
f
 
C
D
4
+
C
D
2
5
h
i
g
h
F
o
x
P
3
+
C
D
1
2
7
-
 
i
n
 
C
D
4
 
T
 
c
e
l
l
s
p=0,042
Fig. 1 The percentage of CD4? CD25
highFoxP3 ? CD127- Tregs
in CD4 T cell population in peripheral blood of JIA patients (n = 12)
and healthy controls (n = 29)
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Fig. 2 Differences in RFI of FoxP3 expression in CD4? CD25
high-
FoxP3 ? CD127- Tregs in peripheral blood of JIA patients (n = 12)
and healthy controls (n = 29). Counting formula is shown in Results
section
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Fig. 3 The percentage of CD71 positive cells in Tregs in peripheral
blood of JIA patients (n = 12) and healthy controls (n = 20)
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123(40.61; 244.07) for JIA and 35.7 (28.94; 53.24) for
controls).
In peripheral blood of JIA patients, the inhibition of
proliferation of CD4? CD25- cells by CD4? CD25?
T cells was 37.9%, and it was signiﬁcantly lower in com-
parison with healthy controls (55.7%, P = 0.046). The
results of this experiment are shown in Fig. 4.
Discussion
In our study, we identiﬁed Tregs as CD4? CD25
high-
FoxP3 ? CD127- T cells. It means that we classiﬁed
CD4CD25
high T cells as Tregs only when they showed
FoxP3 expression and were negative for CD127 expres-
sion. In our JIA group, we saw signiﬁcantly lower per-
centage of Tregs in peripheral blood than in control group.
We are aware that our JIA patient group was small but SD
was quite small, which let us to obtain signiﬁcant results.
Our ﬁndings are similar to that published by Kleer et al.
[12] that concerned bigger group of JIA patients (n = 60
and n = 34) as well as the results of studies performed by
Cao et al. [24]( n = 165, but in this paper Foxp3 was not
assessed) or recently by Olivito et al. [38]( n = 65).
There are several explanations for the decreased per-
centage of Tregs in JIA patients. One of them is that during
inﬂammatory process, which occurs in JIA, Tregs are
attracted to the sites of inﬂammation, especially to the
affected joints. That is the reason for the decreased number
of Tregs in peripheral blood. Many authors observed
increased inﬁltration of functional Tregs in synovial ﬂuid
aspirated from affected joints [12, 18, 22–24, 33, 39]. Of
course, Tregs can proliferate in joints. Unfortunately, we
did not have the opportunity to examine synovial ﬂuid from
affected joints.
Our results obtained from co-culture experiments
showed that notonlywas the number of Tregs in JIA limited
but also their suppressive activity was reduced. Median
inhibition of proliferation of CD4? CD25- T cells in JIA
patients was 37.9%. Moreover in some patients, low sup-
pressive activity (to 2.9 and 6.6%) was observed, while in
healthy controls, the mean value was 55.67% with the
lowest suppressive activity achieved, i.e., 43.3%. We did
not observe any correlation between clinical features and
the level of proliferation inhibition in JIA patients.
Because both groups in the performed study were rela-
tively small and the dispersion level was quite big, it was
really hard to use any statistic method.
This ﬁnding is in agreement with some others results,
however, showing signiﬁcant decrease in suppressive
capacity of Tregs or just the tendency [20, 22]. The
remaining authors did not ﬁnd any decrease in suppressive
activity of Tregs from RA or JIA patients [12, 18, 21]. Low
suppressive capacity may be caused by the interaction
between antigen-presenting cells (APCs) and Tregs, which
is altered by overexpression of co-stimulatory molecules
(CD80, CD86, CD40) on APCs. Such mechanism was
described by van Amelsdorf et al. [22] for synovial ﬂuid
monocytes. In rheumatoid diseases the interaction between
Tregs and effector T cells was also affected. CD4? CD25-
T cells were less sensitive to suppression by Tregs [12, 22].
Cao et al. [24] showed that CD25
brightCD4? T cells,
known as activated memory T cells, express CD71. RA
patients, in comparison with healthy controls, showed
higher intensity of the CD71 staining in CD25
brightCD4?
population. In a paper published by Havryluk et al. [40],
the authors presented signiﬁcantly increased expression of
CD71 on peripheral blood lymphocytes than in healthy
control group; however, the study did not focus on Tregs.
In our results, Tregs obtained from JIA patients showed
higher expression of this activation marker than that from
healthy control’s Tregs. Our patients were in active phase
of the disease—4 of them (25%) were at the onset of the
disease, most of them had high ESR level (9/12, 75%) and
CRP concentration in serum (5/12, 42%). We consider
these results cautiously, because we did not check FoxP3
expression in the same tube as the expression of CD71,
CD127, CD4, and CD25 antigens.
Not only the criteria of identiﬁcation, but also the
degree, duration, and subtype of JIA can inﬂuence Tregs
status. In our study, we showed the data obtained from
patients with OA and PA. The comparison of result
obtained for these two groups did not reveal any differ-
ences; however, as we mention above, our groups were
relatively small. De Kleer et al. [12] showed that persistent
OA JIA patients had signiﬁcantly higher number of
control group JIA
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Fig. 4 Individual inhibition of proliferation of CD4? CD25- T cells
by CD4? CD25? T cells collected from peripheral blood of JIA
patients (n = 7) and healthy controls (n = 6). Cultures were stimu-
lated with PHA for 72 h, proliferation was measured for last 18 h
using [
3H] incorporation. Counting formula is shown in Methods
section
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bright Treg in peripheral blood than extended
OA JIA patients. Lawson et al. [18] observed that in the
peripheral blood of early active RA patients comparably
smaller proportion of CD4? CD25
high T cells was found
than in patients with reactive arthritis.
In our study, we focus on cells that apart from CD4 and
CD25
high were positive for FoxP3 and negative for CD127.
According to these criteria, the patients with JIA had sta-
tistically lower percentage of Tregs in peripheral blood
comparing to healthy controls. We also showed that
CD4CD25
high cell sorted from peripheral blood of JIA
patients have statistically lower ability to suppress
CD4CD25- T cells proliferation in comparison with cells
obtained from healthy controls. Better identiﬁcation and
characterization of Tregs in JIA is needed, because the
decrease in the number of these cells may lead to down-
regulation of T cells tolerance and exacerbate the inﬂam-
matory processes. Some authors postulate that abnormal
T-cell regulation may underline the persistent inﬂammation
characteristic of rheumatoid diseases [18].
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